Physician profile
Rishu Gupta
NPI 1942620869
$9,073.37
in general payments reported to CMS, 2019-2025
30 companies · $1,412 in 2025
The $1,412 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,283 · 2020: $290 · 2021: $2,150 · 2022: $1,133 · 2023: $1,587 · 2024: $1,220 · 2025: $1,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,920 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,920.14 |
| Education | $297.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,548.22 | 2019-2024 | |
| Janssen Biotech, INC. | $1,333.37 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $770.68 | 2020-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $644.89 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Genzyme Corporation | $621.08 | 2019-2025 | |
| Pfizer INC. | $570.74 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $447.10 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $408.75 | 2023-2025 | Sotyktu |
| Ucb, INC. | $327.67 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $266.40 | 2019-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $216.91 | 2019-2022 | |
| Dermira, INC. | $207.45 | 2019-2020 | |
| Incyte Corporation | $191.65 | 2022-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $179.86 | 2019-2022 | |
| Almirall LLC | $168.92 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.37 | 2022-2025 | Spevigo, Cyltezo |
| Teva Pharmaceuticals USA, INC. | $127.43 | 2021 | |
| Portola Pharmaceuticals, LLC | $126.35 | 2020 | |
| Amgen INC. | $110.04 | 2019-2025 | Otezla |
| Galderma Laboratories, L.P. | $105.62 | 2022-2025 | Nemluvio |
| Biofrontera INC. | $101.09 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Vyne Pharmaceuticals INC. | $97.67 | 2021 | |
| Lilly USA, LLC | $93.15 | 2019-2023 | Olumiant, Taltz |
| Arcutis Biotherapeutics, INC. | $86.47 | 2023-2025 | Zoryve |
| Hill Dermaceuticals, INC. | $80.02 | 2025 | Tolak |
| Aclaris Therapeutics, INC. | $43.12 | 2019 | |
| Dusa Pharmaceuticals, INC. | $24.23 | 2019 | |
| Revance Therapeutics, INC. | $20.99 | 2024 | Daxxify |
| Tempus Ai, INC | $18.18 | 2024 | Merlin Test |
| Organon LLC | $3.95 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rishu Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.